Orthocell has today published its Quarterly Report for the period ended 31 March 2024.<\/p>\n
Highlights for this Quarter include:<\/p>\n
\u25cf Increasing revenue driven by growth in new product sales. Year to date revenue of $4.88 million is up 40.7% from $3.47 million for the same period last year.
\n\u25cf Successful completion of a $3.5 million strategic placement
\n\u25cf Strong balance sheet with $20.1m cash at bank at the end of the quarter
\n\u25cf Strengthening the Board with appointment of the Hon Kim Beazley AC
\n\u25cf Successful completion of all nerve repair surgeries in Remplir\u2122 US market authorisation study
\n\u25cf Submission of Singapore Regulatory Application for Remplir\u2122 in February 2024<\/p>\n
Orthocell Managing Director, Paul Anderson, said:<\/p>\n
\u201cOrthocell has completed a very solid quarter, growing revenues whilst strengthening the balance sheet and share register. I am very pleased with the performance of our distribution partners and the continued increase in product adoption. With a highly respected and experienced Board now in place, we are in a strong position to continue to gain commercial traction and drive Remplir, our breakthrough nerve repair device, into global markets.\u201d<\/p>\n